Search clinical trials for: Ipilimumab

Total 838 results

University of Utah

Not yet recruiting

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma (NeoRelapse)

Melanoma

United States
GERCOR - Multidisciplinary Oncology Cooperative...

Recruiting

Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy (NIPIRESCUE)

Metastatic Colorectal Cancer

France
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO (BELLINI)

Breast Cancer

Netherlands
Intergroupe Francophone de Cancerologie Thoracique

Active, not recruiting

Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (DICIPLE)

Non-Small Cell Lung Cancer Metastatic

France
Canadian Cancer Trials Group
Bristol-Myers Squibb; Cancer Research Institute, New York City; Personal Genome...

Terminated

Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (NIMBLe)

Advanced Solid Tumors

United States, Canada
University of Michigan Rogel Cancer Center
Memorial Sloan Kettering Cancer Center; University of California, San Francisco

Active, not recruiting

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT)

Solid Tumor | Metastatic Cancer | Metastatic Castration Resistant Prostate Cancer

United States
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (INTEGA)

Gastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric Cancer

Germany
University of Michigan Rogel Cancer Center

Terminated

Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery

Metastatic Melanoma | Brain Metastases

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive

Prostate Cancer

Australia, United States, Chile, Spain, France, Italy, United Kingdom, Germany, Netherlands
Alona Zer
Bristol-Myers Squibb

Unknown

Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)

Classic Kaposi Sarcoma

Israel
Bristol-Myers Squibb

Completed

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Neoplasm Metastasis | Prostate Cancer

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

Melanoma

United States
Odense University Hospital
Zealand University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark and other collaborators

Recruiting

Immunotherapy in Patients With Early dMMR Rectal Cancer (RESET-R)

Cancer of Rectum

Denmark
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma (ADJORL1)

Head and Neck Squamous Cell Carcinoma

France
Intergroupe Francophone de Cancerologie Thoracique
Federation Francophone de Cancerologie Digestive; GERCOR - Multidisciplinary...

Active, not recruiting

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC)

Neuroendocrine Carcinoma

France
CytomX Therapeutics

Terminated

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Solid Tumor | Unresectable or Metastatic Melanoma

Korea, Republic of, United States, Netherlands, Spain, Australia
University of Louisville
James Graham Brown Cancer Center

Completed

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

Metastatic Melanoma

United States
Bristol-Myers Squibb

Completed

Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma (CheckMate 401)

Melanoma

Australia, France, Italy, Belgium, Finland, Austria, Ireland, Sweden, Switzerland, United Kingdom, Germany, Norway
Bristol-Myers Squibb

Completed

A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

Melanoma

Italy, France, Spain, Australia
Center Trials & Treatment
BioGene Pharmaceutical Inc.

No longer available

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

Glioblastoma | Glioma of Brain

Bosnia and Herzegovina, Albania, Bulgaria, Croatia, Romania, Russian Federation, Serbia, Switzerland
Bristol-Myers Squibb

Completed

Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients

Melanoma

Japan
Bristol-Myers Squibb

No longer available

Compassionate Use Trial for Unresectable Melanoma With Ipilimumab

Melanoma

Brazil
The Netherlands Cancer Institute

Not yet recruiting

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma (MARIANE)

Melanoma

Netherlands
Brown University
Bristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...

Active, not recruiting

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Extra Renal Origin | Clear Cell Adenocarcinoma

United States
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer (RAMONA)

Esophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer Nos

Germany
Bristol-Myers Squibb

Completed

Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases

Melanoma

United States
Bristol-Myers Squibb

No longer available

Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma (CheckMate218)

Malignant Melanoma

United States, Canada
Chiang Mai University

Completed

Efficacy of Topiramate for Hospitalized Patients With Alcoholism (ETHoPA-R)

Alcohol Dependence

Thailand
Bristol-Myers Squibb

Completed

Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Malignant Melanoma

United States
CoImmune

Terminated

Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

United States
Lytix Biopharma AS
ICON plc; Theradex

Completed

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Melanoma | Lymphoma | Cancer | Breast Cancer | Head and Neck Cancer | Triple-Negative Breast Cancer

United Kingdom, France, Norway, Belgium, Italy
National Cancer Institute (NCI)

Terminated

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Previously Treated Myelodysplastic... and other conditions

United States
Inge Marie Svane

Recruiting

Melanoma Metastasized to the Brain and Steroids (MEMBRAINS)

Malignant Melanoma

Denmark
Masonic Cancer Center, University of Minnesota

Completed

Radiation and Combination Immunotherapy for Melanoma

Metastatic Melanoma

United States
University Hospital Heidelberg
German Cancer Research Center

Completed

Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial

Colorectal Cancer Metastatic | Pancreatic Cancer Metastatic

Germany
ERLINDA M GORDON

Recruiting

LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma (LINNOVATE)

Advanced Soft-tissue Sarcoma

United States
Brown University
Bristol-Myers Squibb

Recruiting

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

Non Small Cell Lung Cancer

United States
Abramson Cancer Center at Penn Medicine

Recruiting

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

Melanoma | Melanoma Stage III

United States
Bristol-Myers Squibb

Completed

Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer

Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line

United States
Takeda

Completed

Double Blind Comparative Study of TAK-875

Diabetic Patients

Japan
Bristol-Myers Squibb

Completed

Study of MDX-010 in Stage IV Breast Cancer

Adenocarcinoma | Breast Cancer

United States
Anaveon AG

Recruiting

A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

Advanced Solid Tumor | Metastatic Melanoma | Melanoma (Skin) | Cutaneous Melanoma | Adult Disease

United States, Spain, Germany, France, Italy
The Netherlands Cancer Institute
Genzyme, a Sanofi Company

Recruiting

Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC (RAD-IO)

Carcinoma, Non-Small-Cell Lung

Netherlands
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma (HIPANIV)

Hepatocellular Carcinoma

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

Nerve Sheath Tumors

United States
The Netherlands Cancer Institute
4SC

Active, not recruiting

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI)

Malignant Melanoma Stage III

Netherlands
NYU Langone Health

Active, not recruiting

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb; Northwestern University; Oregon Health and Science University

Active, not recruiting

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
Ferring Pharmaceuticals

Active, not recruiting

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

Metastatic Castration Sensitive Prostate Cancer

United States
Bristol-Myers Squibb

Terminated

A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

Renal Cell Carcinoma

Canada, United States

Search clinical trials for: Ipilimumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations